The OPAT opportunity for beta-lactam individualization.

Lindsey M Childs-Kean Christina G RiveraVeena VenugopalanMadelyn J JohnsonErin F Barreto

Published in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2024)

Beta-lactam therapeutic drug monitoring has been growing in prevalence in the acute care hospital setting. Expansion of its use to outpatient parenteral antimicrobial therapy requires careful consideration of potential logistical and therapeutic barriers.

Keyphrases

acute care
gram negative
risk factors
staphylococcus aureus
stem cells
emergency department
climate change
mesenchymal stem cells
bone marrow
adverse drug